Stock markets gained on Wednesday, as news of a working COVID-19 vaccine seemed to inoculate investors against worry about surging infections in Europe and the United States, while the kiwi rose as traders thought the central bank sounded upbeat.

Global stocks up as vaccine shields against second-wave worries

News of a breakthrough in the race to find a COVID-19 vaccine sparked one of the heaviest trading days since the height of the pandemic crisis, according to early data analysed by Reuters, with nearly $2 trillion (1.51 trillion pounds) changing hands on Monday.

Nearly $2 trillion traded on COVID-19 vaccine news

Scientists on Monday said initial trial results for Pfizer Inc and BioNTech's coronavirus vaccine far outpaced their expectations for protection against a completely new disease, but that many questions remain unanswered.

Pfizer COVID-19 vaccine: What does '90% effective' mean?

Work to distribute the experimental COVID-19 vaccine developed by Pfizer Inc and BioNTech SE is gearing up after the companies announced successful interim data earlier on Monday, but it will not be coming to local pharmacies for the general public any time soon.

Why Pfizer’s ultra-cold COVID-19 vaccine will not be at the local pharmacy any time soon

The trial of a Chinese vaccine has been suspended in Brazil after a 'serious adverse event'. China is not the only player in the vaccine race. WION's Palki Sharma tells you more about the candidates in the global vaccine hunt.

Gravitas: Chinese vaccine triggers 'serious adverse event',  Brazil suspends trials

India: Sensex trading above 43,500 mark

Pfizer vaccine news sends stock markets soaring

Pfizer Inc's experimental COVID-19 vaccine is more than 90% effective based on initial trial results, the drugmaker said on Monday, a major victory in the war against a virus that has killed over a million people and battered the world's economy.

Pfizer vaccine trial success signals breakthrough in pandemic battle

Pfizer, BioNTech initial vaccine results impress, but scientists remain cautious

A study claimed vaccines can take an average of 10 years to develop. But scientists may come up with a vaccine for the Wuhan Coronavirus in less than a year. Fast-tracking a vaccine has also raised the risks. WION's Palki Sharma tells you why the urgency could compromise the process.

Gravitas: Hunt for a vaccine, The hefty cost for cutting corners

A second wave is sweeping through major countries across the world: +Major European Countries are imposing restrictions again +Spain & France have reached 1 million cases +US could be staring at a 'third surge' in cases WION's Palki Sharma tells you more.

Gravitas: Wuhan Coronavirus Pandemic, Tracking the second wave

Trials for a vaccine for the Wuhan Coronavirus are being fast-tracked. Political leaders are promising vaccines for votes. But is anyone talking about safety? WION's Palki Sharma tells you how a vaccine for the Wuhan virus has become a subject of politics and nationalism.

Gravitas: Will you take a vaccine that could make you sick?

Sputnik V, the Russian vaccine against coronavirus will be tested on 100 volunteers in India. Indian Central Drugs Standard Control Organisation`s Drug Controller General (DCGI) was quoted by Sputnik News in this regard. Dr Reddy's Laboratories has been granted permission to conduct the tests. Date and time of the tests however, will be determined by the company.

Sputnik quoted the organisation as saying that the vaccine will be tested in the second phase of its clinical trials before moving on to phase 3.

According to a government official, Dr Reddy`s Lab has stated that in phase 2 clinical trial--"would include 100 subjects and for phase 3, it would take 1400 subjects.

"Once the pharma company would submit the safety and immunogenicity data of phase 2, it would be analysed by the expert panel and then they can proceed for the phase 3 trial," the official added.

On October 13, ANI had reported that Dr Reddy`s Laboratories re-applied fresh protocol to DCGI in order to seek its approval for conducting phase 2 and 3 clinical trials of the Russian COVID-19 vaccine.It may be noted that on October 5, the Subject Expert Committee (SEC) had done a thorough evaluation of the previous application submitted by Dr Reddy`s lab.&nbsp;

Thereafter, the SEC had directed the pharma company to apply with a revised protocol along with more information. The Indian drugmaker has joined hands with the Russian Direct Investment Fund (RDIF) to conduct clinical trials of the Sputnik V vaccine as well as its distribution. As per the RDIF, it will supply 100 million doses of its potential COVID-19 vaccine to India drug company Dr Reddy`s Lab.

Last month, Kirill Dmitriev, CEO, RDIF informed that Russia is in close dialogue with the Indian government and drug manufacturers of India regarding localisation of production of its Sputnik V vaccine in India.

Also, a prestigious medical journal The Lancet had published the results of clinical trials of Phase I-II of the Russian vaccine demonstrating its safety and efficacy.On August 11, the Sputnik V vaccine candidate developed jointly by RDIF and the Gamaleya National Research Center of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world`s first registered vaccine against COVID-19.According to Russian researchers, Sputnik V is a human adenoviral vector vaccine that fights against coronavirus disease.

(With PTI inputs)

Sputnik V, the Russian vaccine against coronavirus will be tested on 100 volunteers in India. Indian Central Drugs Standard Control Organisation`s Drug Controller General (DCGI) was quoted by Sputnik News in this regard.

Sputnik V, the Russian vaccine against coronavirus will be tested on 100 volunteers in India. Indian Central Drugs Standard Control Organisation`s Drug Controller General (DCGI) was quoted by Sputnik News in this regard. Dr Reddy's Laboratories has been granted permission to conduct the tests. Date and time of the tests however, will be determined by the company. Sputnik quoted the organisation as saying that the vaccine will be tested in the second phase of its clinical trials before moving on to phase 3. According to a government official, Dr Reddy`s Lab has stated that in phase 2 clinical trial--"would include 100 subjects and for phase 3, it would take 1400 subjects. "Once the pharma company would submit the safety and immunogenicity data of phase 2, it would be analysed by the expert panel and then they can proceed for the phase 3 trial," the official added. On October 13, ANI had reported that Dr Reddy`s Laboratories re-applied fresh protocol to DCGI in order to seek its approval for conducting phase 2 and 3 clinical trials of the Russian COVID-19 vaccine.It may be noted that on October 5, the Subject Expert Committee (SEC) had done a thorough evaluation of the previous application submitted by Dr Reddy`s lab. Thereafter, the SEC had directed the pharma company to apply with a revised protocol along with more information. The Indian drugmaker has joined hands with the Russian Direct Investment Fund (RDIF) to conduct clinical trials of the Sputnik V vaccine as well as its distribution. As per the RDIF, it will supply 100 million doses of its potential COVID-19 vaccine to India drug company Dr Reddy`s Lab. Last month, Kirill Dmitriev, CEO, RDIF informed that Russia is in close dialogue with the Indian government and drug manufacturers of India regarding localisation of production of its Sputnik V vaccine in India. Also, a prestigious medical journal The Lancet had published the results of clinical trials of Phase I-II of the Russian vaccine demonstrating its safety and efficacy.On August 11, the Sputnik V vaccine candidate developed jointly by RDIF and the Gamaleya National Research Center of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world`s first registered vaccine against COVID-19.According to Russian researchers, Sputnik V is a human adenoviral vector vaccine that fights against coronavirus disease. (With PTI inputs)

Russia's Sputnik V vaccine against COVID-19 will be tested on 100 Indian volunteers

Covaxin, the vaccine candidate developed by Bharat Biotech India Limited (BBIL) in collaboration with Indian Council of Medical Research (ICMR), has received approvals from India’s drug control authority, Drugs Controller General of India (DCGI's) Expert Committee for the initiation of the final and Phase III clinical trials.

The expert committee met on October 20 to give its nod to Phase III trials and suggested some 'minor amendments' in the protocol.

"In continuation of the SEC meeting dated 05.10.2020, the firm presented their data from Phase I and II along with animal challenge data in two species including NHP on the Inactivated Corona Virus Vaccine (BBV152) along with the proposal to conduct event-driven Phase III clinical trial to assess the efficacy of the vaccine," the expert panel said in a statement on Tuesday.

Earlier in September, Bharat Biotech had informed that Covaxin had proved to be effective in inducing immunity against COVID-19 in animals. The firm had stated that the two-dose vaccination regimen of inactivated SARS-CoV-2 vaccine candidates was administered in 20 rhesus macaques which were divided into four groups equally.

Bharat Biotech, along with Zydus Cadila and Serum Institute of India, which is conducting clinical trials on Oxford University-AstraZeneca vaccine, are some of the frontrunners in Covid-19 vaccine development in India.

(With inputs from agencies)

Covaxin, the vaccine candidate developed by Bharat Biotech India Limited (BBIL) in collaboration with Indian Council of Medical Research (ICMR), has received approvals from India’s drug control authority, Drugs Controller General of India (DCGI's) Expert Committee for the initiation of the final and Phase III clinical trials.

Covaxin, the vaccine candidate developed by Bharat Biotech India Limited (BBIL) in collaboration with Indian Council of Medical Research (ICMR), has received approvals from India’s drug control authority, Drugs Controller General of India (DCGI's) Expert Committee for the initiation of the final and Phase III clinical trials. The expert committee met on October 20 to give its nod to Phase III trials and suggested some 'minor amendments' in the protocol. "In continuation of the SEC meeting dated 05.10.2020, the firm presented their data from Phase I and II along with animal challenge data in two species including NHP on the Inactivated Corona Virus Vaccine (BBV152) along with the proposal to conduct event-driven Phase III clinical trial to assess the efficacy of the vaccine," the expert panel said in a statement on Tuesday. Earlier in September, Bharat Biotech had informed that Covaxin had proved to be effective in inducing immunity against COVID-19 in animals. The firm had stated that the two-dose vaccination regimen of inactivated SARS-CoV-2 vaccine candidates was administered in 20 rhesus macaques which were divided into four groups equally. Bharat Biotech, along with Zydus Cadila and Serum Institute of India, which is conducting clinical trials on Oxford University-AstraZeneca vaccine, are some of the frontrunners in Covid-19 vaccine development in India. (With inputs from agencies)

Bharat Biotech's Covaxin receives approval for Phase III trials: Reports

9 people in South Korea died after a shot of the flu vaccine. But authorities found no links between the vaccine and their deaths. But the incident has brought back fears of vaccines. WION's Palki Sharma tells you why the 'anti-vaxxer' movement is growing during the pandemic.

Gravitas: Were 9 South Koreans killed by a flu vaccine shot?

In South Korea, nine people have lost their lives after getting flu shots in the last week. This has raised questions about the safety imbued in the vaccine.&nbsp;

South Korea recently upped its inoculation programme to ease the complications caused by COVID-19, and to decrease the burden on the country’s healthcare system.

On Wednesday alone, five new deaths were recorded. However, authorities do not plan to halt seasonal vaccination programme.&nbsp;

Also read:&nbsp;<a href="http://13.235.153.162/world/five-south-koreans-die-after-getting-flu-shots-sparking-vaccine-fears-336877" hreflang="en">Five South Koreans die after getting flu shots, sparking vaccine fears</a>

Investigations are underway to ascertain the cause of deaths. The authorities are conducting post mortars to find any potential link. Preliminary investigations did not point to any link.

"We have reviewed whether it is appropriate to continue the vaccination or better to suspend and wait for the results," country’s health official Kim Joong-gon said during a briefing.&nbsp;

"We came to the conclusion that the deaths had no direct relations&nbsp;with the vaccination given the limited data we have now and without detailed post mortem reports”, Joong-gon added.

The health official added that out of the six victims, five had underlying health conditions. Additionally, no toxic substances have been found in the vaccine, which was given to many others. Reportedly, among the dead are a 17-year-old boy and a man aged above 70.

Also read:&nbsp;<a href="http://13.235.153.162/entertainment/south-koreas-pop-culture-machine-boosts-netflixs-international-growth-source-336777" hreflang="en">South Korea's pop culture machine boosts Netflix's international growth: source</a>

As winter nears, the country intends to mass inoculate its population to ease the stress caused by the ongoing COVID-19 pandemic.

Just weeks ago, the country’s national vaccine programme was suspended over safety concerns. Reportedly, 5 million doses that require refrigeration at all times were exposed to room temperatures while being transported.

Out of the 19 million eligible for free inoculation, 8.36 million people have already received the vaccine.&nbsp;

In South Korea, nine people have lost their lives after getting flu shots in the last week. This has raised questions about the safety imbued in the vaccine. South Korea recently upped its inoculation programme to ease the complications caused by COVID-19, and to decrease the burden on the country’s healthcare system.

In South Korea, nine people have lost their lives after getting flu shots in the last week. This has raised questions about the safety imbued in the vaccine. South Korea recently upped its inoculation programme to ease the complications caused by COVID-19, and to decrease the burden on the country’s healthcare system. On Wednesday alone, five new deaths were recorded. However, authorities do not plan to halt seasonal vaccination programme. Also read: Five South Koreans die after getting flu shots, sparking vaccine fears Investigations are underway to ascertain the cause of deaths. The authorities are conducting post mortars to find any potential link. Preliminary investigations did not point to any link. "We have reviewed whether it is appropriate to continue the vaccination or better to suspend and wait for the results," country’s health official Kim Joong-gon said during a briefing. "We came to the conclusion that the deaths had no direct relations with the vaccination given the limited data we have now and without detailed post mortem reports”, Joong-gon added. The health official added that out of the six victims, five had underlying health conditions. Additionally, no toxic substances have been found in the vaccine, which was given to many others. Reportedly, among the dead are a 17-year-old boy and a man aged above 70. Also read: South Korea's pop culture machine boosts Netflix's international growth: source As winter nears, the country intends to mass inoculate its population to ease the stress caused by the ongoing COVID-19 pandemic. Just weeks ago, the country’s national vaccine programme was suspended over safety concerns. Reportedly, 5 million doses that require refrigeration at all times were exposed to room temperatures while being transported. Out of the 19 million eligible for free inoculation, 8.36 million people have already received the vaccine.

Panic grips South Korea as nine people die after receiving flu shots

As over 200 companies compete to unveil the first successful covid-19 vaccine. Now the main issue of concern is if the vaccine has unexpected side effects then who would foot the bill in poor countries. Watch report.

Who will be liable for vaccine side effects? Question on financial claims still uncovered | COVID-19 Pandemic

India generated 18,006 tonnes of COVID-19 biomedical waste in the last four months, with Maharashtra contributing the maximum (3,587 tonnes) to it, according to a Central Pollution Control Board (CPCB) data.

Around 5,500 tonnes of COVID-19 waste was generated across the country in September - the maximum for a month so far.

According to the data received from state pollution control boards, since June, all states and Union Territories have generated 18,006 tonnes of COVID-19-related biomedical waste which is being collected, treated and disposed of by 198 common biomedical waste treatment facilities (CBWTFs).

COVID-19 biomedical waste could include PPE kits, masks, shoe covers, gloves, human tissues, items contaminated with blood, body fluids like dressings, plaster casts, cotton swabs, beddings contaminated with blood or body fluid, blood bags, needles, syringes etc.

According to the data, Maharashtra generated 3,587 tonnes of COVID-19 waste in four months since June, followed by Tamil Nadu (1,737 tonnes), Gujarat (1,638 tonnes), Kerala (1,516 tonnes), Uttar Pradesh (1,432 tonnes), Delhi (1,400 tonnes), Karnataka (1,380 tonnes) and West Bengal (1,000 tonnes).

Around 5,490 tonnes of such waste was generated in September, with Gujarat contributing the maximum 622 tonnes, followed by Tamil Nadu (543 tonnes), Maharashtra (524 tnnes), Uttar Pradesh (507 tonnes) and Kerala (494 tonnes).

Delhi generated 382 tonnes of COVID-19 bio-medical waste in September, according to the CPCB data.

Around 5,240 tonnes of COVID-19 waste was generated in August, of which 1,359 tonnes was in Maharashtra, and 588 tonnes each in Kerala and Karnataka.

In July, the country generated 4,253 tonnes of COVID-19 waste, with Maharashtra (1,180), Karnataka (540) and Tamil Nadu (401) being the top three contributors.

India generated 3,025 tonnes of COVID-19 waste in June, with Maharashtra alone accounting for 524 tonnes, followed by Gujarat (350 tonnes), Delhi (333 tonnes) and Tamil Nadu (312 tonnes) The CPCB had in March issued specific guidelines for handling, treatment and disposal of such waste at healthcare facilities, quarantine centres, homes, sample collection centers, laboratories, pollution control boards, urban local bodies and common biomedical waste treatment facilities (CBMWTFs).

The apex pollution body had in May developed the "COVID19BWM" mobile application to monitor coronavirus-related biomedical waste and to compile the data through electronic manifest system.

This application tracks COVID-19 waste at the time of generation, collection and disposal.

The Supreme Court has made it mandatory for all urban local bodies and state pollution control boards to use the mobile application for tracking biomedical waste daily in a bid to ensure that the waste is collected, transported and sent to the registered CBMWTFs.

The directions came on July 30 on recommendations made in a report by the Environment Pollution (Prevention and Control) Authority.

As on Monday, India's COVID-19 caseload stands at 71.2 lakhs while the death toll is 1.09 lakh.

India generated 18,006 tonnes of COVID-19 biomedical waste in the last four months, with Maharashtra contributing the maximum (3,587 tonnes) to it, according to a Central Pollution Control Board (CPCB) data.

India generated 18,006 tonnes of COVID-19 biomedical waste in the last four months, with Maharashtra contributing the maximum (3,587 tonnes) to it, according to a Central Pollution Control Board (CPCB) data. Around 5,500 tonnes of COVID-19 waste was generated across the country in September - the maximum for a month so far. According to the data received from state pollution control boards, since June, all states and Union Territories have generated 18,006 tonnes of COVID-19-related biomedical waste which is being collected, treated and disposed of by 198 common biomedical waste treatment facilities (CBWTFs). COVID-19 biomedical waste could include PPE kits, masks, shoe covers, gloves, human tissues, items contaminated with blood, body fluids like dressings, plaster casts, cotton swabs, beddings contaminated with blood or body fluid, blood bags, needles, syringes etc. According to the data, Maharashtra generated 3,587 tonnes of COVID-19 waste in four months since June, followed by Tamil Nadu (1,737 tonnes), Gujarat (1,638 tonnes), Kerala (1,516 tonnes), Uttar Pradesh (1,432 tonnes), Delhi (1,400 tonnes), Karnataka (1,380 tonnes) and West Bengal (1,000 tonnes). Around 5,490 tonnes of such waste was generated in September, with Gujarat contributing the maximum 622 tonnes, followed by Tamil Nadu (543 tonnes), Maharashtra (524 tnnes), Uttar Pradesh (507 tonnes) and Kerala (494 tonnes). Delhi generated 382 tonnes of COVID-19 bio-medical waste in September, according to the CPCB data. Around 5,240 tonnes of COVID-19 waste was generated in August, of which 1,359 tonnes was in Maharashtra, and 588 tonnes each in Kerala and Karnataka. In July, the country generated 4,253 tonnes of COVID-19 waste, with Maharashtra (1,180), Karnataka (540) and Tamil Nadu (401) being the top three contributors. India generated 3,025 tonnes of COVID-19 waste in June, with Maharashtra alone accounting for 524 tonnes, followed by Gujarat (350 tonnes), Delhi (333 tonnes) and Tamil Nadu (312 tonnes) The CPCB had in March issued specific guidelines for handling, treatment and disposal of such waste at healthcare facilities, quarantine centres, homes, sample collection centers, laboratories, pollution control boards, urban local bodies and common biomedical waste treatment facilities (CBMWTFs). The apex pollution body had in May developed the "COVID19BWM" mobile application to monitor coronavirus-related biomedical waste and to compile the data through electronic manifest system. This application tracks COVID-19 waste at the time of generation, collection and disposal. The Supreme Court has made it mandatory for all urban local bodies and state pollution control boards to use the mobile application for tracking biomedical waste daily in a bid to ensure that the waste is collected, transported and sent to the registered CBMWTFs. The directions came on July 30 on recommendations made in a report by the Environment Pollution (Prevention and Control) Authority. As on Monday, India's COVID-19 caseload stands at 71.2 lakhs while the death toll is 1.09 lakh.

India generated over 18,000 tonnes COVID-19 waste since June; Maharashtra biggest contributor

Amid growing concern over access to Covid-19 medical products, Moderna has decided not to enforce its patent rights related to its experimental vaccine. Watch report.

Moderna vows not to enforce Covid-19 patents: WHO welcomes move

India has assured Myanmar it would give the country priority on coronavirus vaccine and speed up infrastructure projects in the country during the visit of Army Chief General MM Naravane and Foreign Secretary Harsh Vardhan Shringla's two-day visit.&nbsp;

A Ministry of External Affairs (MEA) release said, "It was also agreed that the cooperation to overcome the challenges posed by the COVID-19 pandemic will be deepened. The FC indicated India’s willingness to prioritise Myanmar in sharing vaccines as and when these become available."

Earlier on Monday, Army Chief and the foreign secretary presented 3,000 vials of Remdesivir to Myanmar's state counsellor Aung San Suu Kyi as a "symbol" of India’s commitment to assist Myanmar in its fight against the pandemic.&nbsp;

The Myanmar foreign ministry mentioned about both countries discussing "possibility of joint production of COVID-19 vaccine".

On the infrastructure front, operationalisation of the Sittwe Port in the early part of 2021 was a key point of discussion. Remember, this was discussed during last week's virtual India Myanmar Foreign Office Consultations also.

The MEA release on the outcome of the visit explained: "Both sides also discussed progress in the ongoing Indian-assisted infrastructure projects such as the Trilateral Highway and the Kaladan Multi-Modal Transit Transport Project."

Sittwe is part of India built mega Kaladan Multi-Modal Transit Transport Project, which will improve connectivity with Myanmar, by creating transport corridor for shipment of cargo from the eastern ports of India to Myanmar.

The release added that both sides "exchanged views on an early initiation of work on fresh initiatives such as the up-gradation of Yamethin Women's Police Academy, Basic Technical Training School and measures to provide long term sustainability to projects such as the Myanmar Institute of Information Technology."

Other than that, India has announced a grant of $2 million for the construction of the border haat bridge at Byanyu/Sarsichauk in Myanmar's Chin State which will provide increased economic connectivity between Mizoram and Myanmar. A quota of 1.5 lakh tonnes of Urad for import from Myanmar till 31 March 2021 was also announced.&nbsp;

During the meet, the army chief and the FS called on State Counsellor Daw Aung San Suu Kyi and the Commander in Chief of Defense Services Senior General Min Aung Hlaing. Army Chief also met Vice Senior General Soe Win, Deputy Commander-in-Chief, Myanmar Armed Services and FS met U Soe Han, Permanent Secretary of Ministry of Foreign Affairs of Myanmar.

India has assured Myanmar it would give the country priority on coronavirus vaccine and speed up infrastructure projects in the country during the visit of Army Chief General MM Naravane and Foreign Secretary Harsh Vardhan Shringla's two-day visit.

India has assured Myanmar it would give the country priority on coronavirus vaccine and speed up infrastructure projects in the country during the visit of Army Chief General MM Naravane and Foreign Secretary Harsh Vardhan Shringla's two-day visit. A Ministry of External Affairs (MEA) release said, "It was also agreed that the cooperation to overcome the challenges posed by the COVID-19 pandemic will be deepened. The FC indicated India’s willingness to prioritise Myanmar in sharing vaccines as and when these become available." Earlier on Monday, Army Chief and the foreign secretary presented 3,000 vials of Remdesivir to Myanmar's state counsellor Aung San Suu Kyi as a "symbol" of India’s commitment to assist Myanmar in its fight against the pandemic. The Myanmar foreign ministry mentioned about both countries discussing "possibility of joint production of COVID-19 vaccine". On the infrastructure front, operationalisation of the Sittwe Port in the early part of 2021 was a key point of discussion. Remember, this was discussed during last week's virtual India Myanmar Foreign Office Consultations also. The MEA release on the outcome of the visit explained: "Both sides also discussed progress in the ongoing Indian-assisted infrastructure projects such as the Trilateral Highway and the Kaladan Multi-Modal Transit Transport Project." Sittwe is part of India built mega Kaladan Multi-Modal Transit Transport Project, which will improve connectivity with Myanmar, by creating transport corridor for shipment of cargo from the eastern ports of India to Myanmar. The release added that both sides "exchanged views on an early initiation of work on fresh initiatives such as the up-gradation of Yamethin Women's Police Academy, Basic Technical Training School and measures to provide long term sustainability to projects such as the Myanmar Institute of Information Technology." Other than that, India has announced a grant of $2 million for the construction of the border haat bridge at Byanyu/Sarsichauk in Myanmar's Chin State which will provide increased economic connectivity between Mizoram and Myanmar. A quota of 1.5 lakh tonnes of Urad for import from Myanmar till 31 March 2021 was also announced. During the meet, the army chief and the FS called on State Counsellor Daw Aung San Suu Kyi and the Commander in Chief of Defense Services Senior General Min Aung Hlaing. Army Chief also met Vice Senior General Soe Win, Deputy Commander-in-Chief, Myanmar Armed Services and FS met U Soe Han, Permanent Secretary of Ministry of Foreign Affairs of Myanmar.

India assures Myanmar Covid vaccine, speeding up infra projects

On the status of major coronavirus vaccine candidates that are underway, WION gets you the development from around the world. Watch report.

COVID-19 Pandemic: Moderna's COVID-19 vaccine appears safe

US President Donald Trump is promising to deliver a free of cost vaccine to all US citizens by mid-October. But top American Health experts say a vaccine won't be available till 2021 Summer. Palki Sharma Upadhyay tells you how vaccines have taken centre stage in the U.S. Presidential race.

Gravitas: Has Trump found a Coronavirus vaccine?

American life finds itself in the middle of a plague that answers to no calendar, ideology or political objective. Just weeks away from the #USElection, the arrival of a vaccine takes the centre stage in American politics.

Vaccine: A guarantee to election success?

The top health experts can be wrong, but the US President&nbsp;<a href="https://www.wionews.com/topics/donald-trump">Donald Trump</a>&nbsp;can never be wrong even in scientific proofs, or so he believes.

On Tuesday, in an interview with Fox News, Trump had claimed that the COVID-19 vaccine will be available after "four weeks, it could be eight weeks." However, hours later at a town hall event, he shortened the wait time by amonth and claimed,&nbsp;"<a href="https://www.wionews.com/world/coronavirus-vaccine-could-be-ready-within-3-4-weeks-donald-trump-327823">We're very close to having a vaccine</a>. We're within weeks of getting it you know — could be three weeks, four weeks."

<a href="https://www.wionews.com/world/us-election-2020-donald-trump-admits-downplaying-seriousness-of-covid-19-326412">Also read|&nbsp;US election 2020: Donald Trump admits 'downplaying' seriousness of COVID-19</a>

So&nbsp;now that a whole day has passed, the timeline was expected to get shorter, and so it did. In an interaction with few local reporters on Wednesday, Trump told them the vaccine will be ready till October, i.e. two weeks.

In a race to win the&nbsp;&nbsp;<a href="https://www.wionews.com/topics/us-election">US elections</a>, which are scheduled for November 03, Trump seems to be ready to play with every possible trick down his sleeve and COVID-19 vaccine happens to be one of them.

The recent claim of the vaccine being ready within two weeks has come after the remarks made in the&nbsp;Senate testimony by Centers for Disease Control and Prevention director Robert Redfield.

On Wednesday, Redfield had told lawmakers that a "very limited" distribution to of the vaccine will be made available to priority groups including first responders, and the timeline for that may be around November or December, clearing that this was not guaranteed. He had also added&nbsp;that full implementation would take many more months at least.

<a href="https://www.wionews.com/world/calm-no-panic-donald-trump-says-he-didnt-lie-about-coronavirus-after-bob-woodwards-book-reveal-326725">Also read|&nbsp;'Calm, no panic': Donald Trump says he didn't lie about coronavirus after Bob Woodward's book-reveal</a>

When asked when would a safe vaccine be available for masses, Redfield has said,&nbsp;"I think we're probably looking at late second quarter, third quarter 2021."

However, Trump quickly dismissed the experts' scientifically-backed information by saying, "I think he made a mistake when he said that. That's just incorrect information."

"We're very close to that vaccine as you know... We think we can start sometime in October," Trump said.

"I believe he was confused," he said of Redfield. "I am just telling you we are ready to go as soon as the vaccine happens."

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
The best defense we currently have against this virus are the important mitigation efforts of wearing a mask, washing your hands, social distancing and being careful about crowds. <a href="https://twitter.com/hashtag/COVID19?src=hash&amp;ref_src=twsrc%5Etfw">#COVID19</a>
— Dr. Robert R. Redfield (@CDCDirector) <a href="https://twitter.com/CDCDirector/status/1306362537924079616?ref_src=twsrc%5Etfw">September 16, 2020</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

This is not the first time a contradiction has occurred between these two. Earlier this week, when Redfield was busy urging people to wear masks to contain the spread of coronavirus, Trump told people to wear masks only when needed and not 'all the time' as they are not very helpful. He even added,&nbsp;"I think there are a lot of problems with masks. It's not more effective than a vaccine."

The comment was also criticised by his rival, Joe Biden, who expressed concern about the president's approach towards the coronavirus.&nbsp;

The top health experts can be wrong, but the US President Donald Trump can never be wrong even in scientific proofs, or so he believes. On Tuesday, in an interview with Fox News, Trump had claimed that the COVID-19 vaccine will be available after "four weeks, it could be eight weeks.

The top health experts can be wrong, but the US President Donald Trump can never be wrong even in scientific proofs, or so he believes. On Tuesday, in an interview with Fox News, Trump had claimed that the COVID-19 vaccine will be available after "four weeks, it could be eight weeks." However, hours later at a town hall event, he shortened the wait time by amonth and claimed, "We're very close to having a vaccine. We're within weeks of getting it you know — could be three weeks, four weeks." Also read| US election 2020: Donald Trump admits 'downplaying' seriousness of COVID-19 So now that a whole day has passed, the timeline was expected to get shorter, and so it did. In an interaction with few local reporters on Wednesday, Trump told them the vaccine will be ready till October, i.e. two weeks. In a race to win the US elections, which are scheduled for November 03, Trump seems to be ready to play with every possible trick down his sleeve and COVID-19 vaccine happens to be one of them. The recent claim of the vaccine being ready within two weeks has come after the remarks made in the Senate testimony by Centers for Disease Control and Prevention director Robert Redfield. On Wednesday, Redfield had told lawmakers that a "very limited" distribution to of the vaccine will be made available to priority groups including first responders, and the timeline for that may be around November or December, clearing that this was not guaranteed. He had also added that full implementation would take many more months at least. Also read| 'Calm, no panic': Donald Trump says he didn't lie about coronavirus after Bob Woodward's book-reveal When asked when would a safe vaccine be available for masses, Redfield has said, "I think we're probably looking at late second quarter, third quarter 2021." However, Trump quickly dismissed the experts' scientifically-backed information by saying, "I think he made a mistake when he said that. That's just incorrect information." "We're very close to that vaccine as you know... We think we can start sometime in October," Trump said. "I believe he was confused," he said of Redfield. "I am just telling you we are ready to go as soon as the vaccine happens." The best defense we currently have against this virus are the important mitigation efforts of wearing a mask, washing your hands, social distancing and being careful about crowds. #COVID19 — Dr. Robert R. Redfield (@CDCDirector) September 16, 2020 × This is not the first time a contradiction has occurred between these two. Earlier this week, when Redfield was busy urging people to wear masks to contain the spread of coronavirus, Trump told people to wear masks only when needed and not 'all the time' as they are not very helpful. He even added, "I think there are a lot of problems with masks. It's not more effective than a vaccine." The comment was also criticised by his rival, Joe Biden, who expressed concern about the president's approach towards the coronavirus.

Trump says top health expert was 'confused' about vaccine, but not him

Around 50,000 people, across several countries, are participating in phase 3 clinical trials of a COVID vaccine developed by the China National Biotec Group

Tracking COVID-19 vaccine: China's phase 3 vaccine proceedings going smooth

India's Health and Family Welfare Minister Harsh Vardhan on September 13, 2020 claimed that India shall have a vaccine ready by March 2021. He even offered to take the first shot himself for receiving COVID-19 vaccine if people have any 'trust deficit'.

India's Health Minister Harsh Vardhan: COVID-19 vaccine to be ready by March 2021

Pharma giant AstraZeneca on Saturday said it had resumed a Covid-19 vaccine trial after getting the all-clear from British regulators, following a pause caused by a UK volunteer falling ill.

"Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so," the company said in a statement.

The vaccine, which is known as Covishield in India, is being develped by Oxford University and AstraZeneca.

AstraZeneca, the pharmaceutical giant, had "voluntarily paused" clinical trials of the Coronavirus vaccine after a volunteer developed an unexplained illness. AstraZeneca called it a routine action but this pause in the clinical trials made headlines everywhere.

The vaccine, being developed by Oxford University and AstraZeneca is considered to be the frotrunner in the race to develop vaccine against coronavirus. If all goes as per the requirements, teh vaccine may be available to public as early as Janury 2021.

In India, the vaccine will be manufactured by Serum Institute of India, the third largest manufacturer of vaccines in the world.Just after&nbsp;AstraZeneca decided to resume vaccine trails, Adar Poonawalla, CEO of Serum Institute said that it was a good news

"As I’d mentioned earlier, we should not jump to conclusions until the trials are fully concluded. The recent chain of events are a clear example why we should not bias the process and should respect the process till the end. Good news, @UniofOxford" he tweeted.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
As I’d mentioned earlier, we should not jump to conclusions until the trials are fully concluded. The recent chain of events are a clear example why we should not bias the process and should respect the process till the end. Good news, <a href="https://twitter.com/UniofOxford?ref_src=twsrc%5Etfw">@UniofOxford</a>. <a href="https://t.co/ThIU2ELkO3">https://t.co/ThIU2ELkO3</a>
— Adar Poonawalla (@adarpoonawalla) <a href="https://twitter.com/adarpoonawalla/status/1304800907327016960?ref_src=twsrc%5Etfw">September 12, 2020</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

After Astrazeneca paused the trails, Serum Institute had said that its trials in India would not stop as they had not encountered any problem. However, Serum Institute paused the trials and Drugs Controller General of India (DCGI) served a notice to it.

(With inputs from AFP)

Pharma giant AstraZeneca on Saturday said it had resumed a Covid-19 vaccine trial after getting the all-clear from British regulators, following a pause caused by a UK volunteer falling ill.

Pharma giant AstraZeneca on Saturday said it had resumed a Covid-19 vaccine trial after getting the all-clear from British regulators, following a pause caused by a UK volunteer falling ill. "Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so," the company said in a statement. The vaccine, which is known as Covishield in India, is being develped by Oxford University and AstraZeneca. AstraZeneca, the pharmaceutical giant, had "voluntarily paused" clinical trials of the Coronavirus vaccine after a volunteer developed an unexplained illness. AstraZeneca called it a routine action but this pause in the clinical trials made headlines everywhere. The vaccine, being developed by Oxford University and AstraZeneca is considered to be the frotrunner in the race to develop vaccine against coronavirus. If all goes as per the requirements, teh vaccine may be available to public as early as Janury 2021. In India, the vaccine will be manufactured by Serum Institute of India, the third largest manufacturer of vaccines in the world.Just after AstraZeneca decided to resume vaccine trails, Adar Poonawalla, CEO of Serum Institute said that it was a good news "As I’d mentioned earlier, we should not jump to conclusions until the trials are fully concluded. The recent chain of events are a clear example why we should not bias the process and should respect the process till the end. Good news, @UniofOxford" he tweeted. As I’d mentioned earlier, we should not jump to conclusions until the trials are fully concluded. The recent chain of events are a clear example why we should not bias the process and should respect the process till the end. Good news, @UniofOxford. https://t.co/ThIU2ELkO3 — Adar Poonawalla (@adarpoonawalla) September 12, 2020 × After Astrazeneca paused the trails, Serum Institute had said that its trials in India would not stop as they had not encountered any problem. However, Serum Institute paused the trials and Drugs Controller General of India (DCGI) served a notice to it. (With inputs from AFP)

AstraZeneca resumes trials of coronavirus vaccine in UK

Drugs Controller General of India (DGCI) has issued a show-cause notice to Serum Institute, the world's third largest vaccine manufacturer over safety issues in COVID-19 vaccine trials. DGCI has asked Serum Institute why trials of Covishield were not stopped in India even when the same vaccine-candidate caused illness in one of the participants of the trials.

Trials of the vaccine in the UK were put on hold after after one of the participants developed an unexplained illness. The vaccine is being developed by AstraZeneca and Oxford Univesrity.

"As part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee," a spokesperson said earlier on Wednesday.

 
Also Read: <a href="https://www.wionews.com/india-news/oxford-university-covid-19-vaccine-trials-in-india-to-continue-despite-pause-in-uk-serum-institute-326243">Oxford University Covid-19 vaccine trials in India to continue despite 'pause' in UK: Serum Institute</a> 
&nbsp;

The company spokesperson also added that in large trials, illnesses will sometimes happen by chance but must be reviewed independently.

Serum Institute, which has been conducting trials of the vaccine in India, said on Wednesday (September 9) that they encountered "no issues".

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<blockquote class="twitter-tweet">
We can't comment much on the UK trials, but they have been paused for further review and they hope to restart soon. As far as Indian trials are concerned, it is continuing &amp; we have faced no issues at all: Serum Institute of India on reports on AstraZeneca halting the trials. <a href="https://t.co/gL7IirfnXy">https://t.co/gL7IirfnXy</a>
— ANI (@ANI) <a href="https://twitter.com/ANI/status/1303631201157042176?ref_src=twsrc%5Etfw">September 9, 2020</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

&nbsp;

"We can't comment much on the UK trials, but they have been paused for further review and they hope to restart soon. As far as Indian trials are concerned, it is continuing &amp; we have faced no issues at all: Serum Institute of India on reports on AstraZeneca halting the trials," Serum Institute was quoted as saying by ANI.

Drugs Controller General of India (DGCI) has issued a show-cause notice to Serum Institute, the world's third largest vaccine manufacturer over safety issues in COVID-19 vaccine trials.

Drugs Controller General of India (DGCI) has issued a show-cause notice to Serum Institute, the world's third largest vaccine manufacturer over safety issues in COVID-19 vaccine trials. DGCI has asked Serum Institute why trials of Covishield were not stopped in India even when the same vaccine-candidate caused illness in one of the participants of the trials. Trials of the vaccine in the UK were put on hold after after one of the participants developed an unexplained illness. The vaccine is being developed by AstraZeneca and Oxford Univesrity. "As part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow review of safety data by an independent committee," a spokesperson said earlier on Wednesday. Also Read: Oxford University Covid-19 vaccine trials in India to continue despite 'pause' in UK: Serum Institute The company spokesperson also added that in large trials, illnesses will sometimes happen by chance but must be reviewed independently. Serum Institute, which has been conducting trials of the vaccine in India, said on Wednesday (September 9) that they encountered "no issues". We can't comment much on the UK trials, but they have been paused for further review and they hope to restart soon. As far as Indian trials are concerned, it is continuing & we have faced no issues at all: Serum Institute of India on reports on AstraZeneca halting the trials. https://t.co/gL7IirfnXy — ANI (@ANI) September 9, 2020 × "We can't comment much on the UK trials, but they have been paused for further review and they hope to restart soon. As far as Indian trials are concerned, it is continuing & we have faced no issues at all: Serum Institute of India on reports on AstraZeneca halting the trials," Serum Institute was quoted as saying by ANI.

Why haven't COVID-19 vaccine trials stopped? DCGI asks Serum Institute over safety concerns

Trials have stopped for the vaccine that was touted to be the frontrunner in the global race to combat coronavirus. In spite of being at the front of the race, trials for the vaccine being developed by AstraZeneca with Oxford University were put on hold.

The decision was taken after one of the participants showed serious and adverse reactions during the trials. When the trails were put on hold, they were being held in the US and UK. The participant suffering from the unexplained illness is expected to recover.

The story was first reported by health news website - Stat News

"Standard review process triggered a pause to vaccination to allow review of safety data,” Stat News&nbsp;quoted AstraZeneca spokesperson as saying.

<div class="ui-state-default" contenteditable="false">
<div class="twitter-block" draggable="false">
<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-setback-for-oxfords-covid-19-vaccine-326394/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>
</div>
<a class="close-mark close-div" href="#" id="jqclosemark">×</a></div>

In May, the US had ordered 300 million doses of the potential vaccine.&nbsp;Earlier this week, Australia announced that it had placed an order for 3.8 million doses with AstraZeneca.&nbsp;

The vaccine race has become highly political. Russian President Vladimir Putin had tested&nbsp;the Sputnik-V on his daughter. It&nbsp;is the vaccine for which there is no trial data available.&nbsp;Then there is China, where Sinovac is injecting its employees and their families with a potential vaccine.&nbsp;Again, it&nbsp;is a vaccine the world knows very little about.

Amidst all these covert trials, the transparency of one vaccine maker comes as a pleasant surprise.

There are still some companies that are not succumbing to political pressure to win the vaccine race. There are still some firms upholding the safety protocols even when political leaders advocate bypassing the critical stages of the trial.

Just yesterday, nine vaccine makers vowed not to cut corners on testing.&nbsp;AstraZeneca was one of the signatories

Others include Bio-N-Tech, Pfizer, Novovax, Sanofi, Glaxo-Smithkline, Johnson &amp; Johnson and Merck

Reacting to paused trials, Australia's Deputy Chief Medical Officer Nick Coatsworth said that the news was a testimony to safety and transparency.

"The fact that we're hearing about it and I'm talking about it, is testimony to the safety and the transparency. Both of which are such critical principles as we continue the race towards an effective COVID-19 vaccine," he said.

British Health Minister Matt Hancock echoed the sentiment.

"Well obviously I'd rather this went completely smoothly. However, we're absolutely clear that safety comes first with the vaccine so there's been a pause while they investigate an incident," he said.

These reactions are not surprising as Australia and UK both have stakes in a potential vaccine.&nbsp;The paused trial is a setback, no matter what British authorities tell you.

The world is in a dire need of a vaccine. The Wuhan virus has already taken 9,00,000 lives but the world needs a vaccine that can save lives, not take more. 
&nbsp;

Trials have stopped for the vaccine that was touted to be the frontrunner in the global race to combat coronavirus. In spite of being at the front of the race, trials for the vaccine being developed by AstraZeneca with Oxford University were put on hold.

Trials have stopped for the vaccine that was touted to be the frontrunner in the global race to combat coronavirus. In spite of being at the front of the race, trials for the vaccine being developed by AstraZeneca with Oxford University were put on hold. The decision was taken after one of the participants showed serious and adverse reactions during the trials. When the trails were put on hold, they were being held in the US and UK. The participant suffering from the unexplained illness is expected to recover. The story was first reported by health news website - Stat News "Standard review process triggered a pause to vaccination to allow review of safety data,” Stat News quoted AstraZeneca spokesperson as saying. × In May, the US had ordered 300 million doses of the potential vaccine. Earlier this week, Australia announced that it had placed an order for 3.8 million doses with AstraZeneca. The vaccine race has become highly political. Russian President Vladimir Putin had tested the Sputnik-V on his daughter. It is the vaccine for which there is no trial data available. Then there is China, where Sinovac is injecting its employees and their families with a potential vaccine. Again, it is a vaccine the world knows very little about. Amidst all these covert trials, the transparency of one vaccine maker comes as a pleasant surprise. There are still some companies that are not succumbing to political pressure to win the vaccine race. There are still some firms upholding the safety protocols even when political leaders advocate bypassing the critical stages of the trial. Just yesterday, nine vaccine makers vowed not to cut corners on testing. AstraZeneca was one of the signatories Others include Bio-N-Tech, Pfizer, Novovax, Sanofi, Glaxo-Smithkline, Johnson & Johnson and Merck Reacting to paused trials, Australia's Deputy Chief Medical Officer Nick Coatsworth said that the news was a testimony to safety and transparency. "The fact that we're hearing about it and I'm talking about it, is testimony to the safety and the transparency. Both of which are such critical principles as we continue the race towards an effective COVID-19 vaccine," he said. British Health Minister Matt Hancock echoed the sentiment. "Well obviously I'd rather this went completely smoothly. However, we're absolutely clear that safety comes first with the vaccine so there's been a pause while they investigate an incident," he said. These reactions are not surprising as Australia and UK both have stakes in a potential vaccine. The paused trial is a setback, no matter what British authorities tell you. The world is in a dire need of a vaccine. The Wuhan virus has already taken 9,00,000 lives but the world needs a vaccine that can save lives, not take more.

Trials of Oxford University's COVID-19 vaccine 'paused', what now?

As the US elections are coming closer, the personal attacks between the two competitors seem to be increasing.

In an&nbsp;address on Monday, the US President Donald Trump demanded an apology from his opponent <a href="https://www.wionews.com/topics/joe-biden">Joe Biden</a> for challenging him on COVID-19 vaccine.

Trump feels Biden's stand on American <a href="https://www.wionews.com/topics/coronavirus-vaccine">COVID-19 vaccines</a> is&nbsp;very "reckless" and he should apologise for the "anti-vaccine rhetoric".

<a href="https://www.wionews.com/world/us-election-2020-kamala-harris-will-never-be-president-of-us-says-donald-trump-325860">Also read|&nbsp;US election 2020: Kamala Harris will never be president of US, says Donald Trump</a>

<a href="https://www.wionews.com/topics/donald-trump">Donald Trump</a>, during a Labor Day news conference in front of the White House, said,&nbsp;"Biden and his very liberal running mate, the most liberal person in Congress by the way - is not a competent person in my opinion, would destroy this country and would destroy this economy - should immediately apologize for the reckless anti-vaccine rhetoric that they are talking right now."

Trump, calling Biden "stupid" said Biden's opinion on the vaccine "undermines science".

The President has announced that he will have the COVID-19 vaccine ready before the upcoming US Presidential elections, that are scheduled for November 03.

<a href="https://www.wionews.com/world/meet-donald-trumps-latest-admirer-noor-bin-ladin-the-niece-of-osama-bin-laden-325838">Also read|&nbsp;Meet Donald Trump's latest admirer - Noor Bin Ladin, the niece of Osama Bin Laden</a>

The comment came after Joe Biden, his opponent in the<a href="https://www.wionews.com/topics/us-election"> US elections 2020</a>, strongly opposed Trump's claim on vaccine, and even questioned if the FDA is being pressurised by the Trump administration to roll out the vaccine early.

Trump also touched upon the recent controversy of him calling the fallen US soldiers as "losers" and "suckers". Dismissing the reports, he said,&nbsp;"The story is a hoax. Who would say a thing like that? Only an animal would say a thing like that."

He also claimed that he is the idle person to bring the country of the pandemic-hit economy recession, as opposed to Joe Biden who, according to Trump, would undo the progress.

As the US elections are coming closer, the personal attacks between the two competitors seem to be increasing. In an address on Monday, the US President Donald Trump demanded an apology from his opponent Joe Biden for challenging him on COVID-19 vaccine.

As the US elections are coming closer, the personal attacks between the two competitors seem to be increasing. In an address on Monday, the US President Donald Trump demanded an apology from his opponent Joe Biden for challenging him on COVID-19 vaccine. Trump feels Biden's stand on American COVID-19 vaccines is very "reckless" and he should apologise for the "anti-vaccine rhetoric". Also read| US election 2020: Kamala Harris will never be president of US, says Donald Trump Donald Trump, during a Labor Day news conference in front of the White House, said, "Biden and his very liberal running mate, the most liberal person in Congress by the way - is not a competent person in my opinion, would destroy this country and would destroy this economy - should immediately apologize for the reckless anti-vaccine rhetoric that they are talking right now." Trump, calling Biden "stupid" said Biden's opinion on the vaccine "undermines science". The President has announced that he will have the COVID-19 vaccine ready before the upcoming US Presidential elections, that are scheduled for November 03. Also read| Meet Donald Trump's latest admirer - Noor Bin Ladin, the niece of Osama Bin Laden The comment came after Joe Biden, his opponent in the US elections 2020, strongly opposed Trump's claim on vaccine, and even questioned if the FDA is being pressurised by the Trump administration to roll out the vaccine early. Trump also touched upon the recent controversy of him calling the fallen US soldiers as "losers" and "suckers". Dismissing the reports, he said, "The story is a hoax. Who would say a thing like that? Only an animal would say a thing like that." He also claimed that he is the idle person to bring the country of the pandemic-hit economy recession, as opposed to Joe Biden who, according to Trump, would undo the progress.

US election 2020: Trump demands apology from Biden for challenging him on vaccines

vaccine

Vaccine, News on Vaccine, stories on Vaccine, articles on Vaccine, Vaccine stories at Wion, Vaccine news, Vaccine latest news